Volume 4 Supplement 2
Involvement of mitochondrial and survival signaling in berberine-induced apoptosis in melanoma cells
© Burgeiro et al; licensee BioMed Central Ltd. 2010
Published: 24 September 2010
Here, we have found that the natural isoquinoline alkaloid berberine induced apoptosis of SK-MEL-2 human melanoma cells, as assessed by an increase in sub-G1 phase (hipodiploidy) in flow cytometry analysis, which involved mitochondria and caspase activation, including caspases 3, 4, 7, 8, and 9. Berberine induced disruption of the mitochondrial transmembrane potential (ΔΨm), released cytochrome c and AIF from mitochondria, as well as increased reactive oxygen species (ROS) production and decreased the ATP/ADP ratio. Ectopic Bcl-XL overexpression inhibited berberine-induced cell death, ΔΨm loss, cytochrome c and AIF release, and ROS generation, thus demonstrating the involvement of mitochondria in the cell death process. Berberine also led to the generation of the p20 cleavage fragment from BAP31, involved in the directing proapoptotic signals between endoplasmic reticulum and mitochondria. Inhibition of ERK phosphorylation, by using the MEK inhibitor PD98059, significantly reduced the berberine concentration required to promote apoptosis. Reduction of the level of BRAF by silencing RNA promoted cell death of melanoma cells and increased berberine-induced apoptosis. These data reveal the involvement of mitochondria in berberine-induced apoptosis in melanoma cells, and the implication of additional signaling processes, such as survival ERK and BRAF signal cascades, that once inhibited facilitate the cell death response triggered by berberine. The results provide novel insights into the mechanisms of berberine-mediated anti-melanoma activity.
This work was supported by grants from the Fundação para a Ciência e Tecnologia (FCT, Portugal): PTDC/QUI-QUI/101409/2008 (to P.J.O.) and SFRH/BD/32943/2006 (to A.B.); Ministerio de Ciencia e Innovación (Spain): SAF2008-02251, and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union (to F.M.); Fondo de Investigación Sanitaria and European Commission: PS09/01915 (to C.G.); Junta de Castilla y León: GR15-Experimental Therapeutics and Translational Oncology Program, and Biomedicine Project 2009 (to F.M.); C.G. is supported by the Ramón y Cajal Program from the Spanish Ministerio de Ciencia e Innovación.
This article is published under license to BioMed Central Ltd.